Key result
Sodium ozagrel combined with atorvastatin significantly increased the total effective rate to 94.0% compared to 80.0% with atorvastatin alone in patients with type 2 diabetes and lacunar cerebral infarction.
Why the study?
Current treatments for cerebral infarction focus on antiplatelet aggregation and improving blood status, but research remains limited to symptom improvement alone.
Does sodium ozagrel combined with atorvastatin improve clinical efficacy and reduce inflammation in patients with type 2 diabetes and lacunar cerebral infarction compared to atorvastatin alone?
Observational (n=82)
No
Does sodium ozagrel combined with atorvastatin improve clinical efficacy and reduce inflammation in patients with type 2 diabetes and lacunar cerebral infarction compared to atorvastatin alone?
Answers are grounded in this paper and cite their sources.
The addition of sodium ozagrel to atorvastatin significantly improved clinical efficacy, reduced inflammatory markers, and improved lipid and glucose profiles in patients with type 2 diabetes and lacunar cerebral infarction without increasing adverse reactions.
BACKGROUND: The main pathological factor of cerebral infarction is atherosclerosis, which is the pathological process of chronic inflammatory diseases such as vascular smooth muscle hyperplasia, inflammatory cell infiltration, extracellular matrix increase, and thrombosis. At present, the focus of clinical treatment is anti-platelet aggregation and improving blood status, and current research is limited to improving symptoms only. AIM: To observe the effect of sodium ozagrel and atorvastatin on type 2 diabetes patients with lacunar cerebral infarction. METHODS: Eighty-two patients with type 2 diabetes and lacunar cerebral infarction admitted to our hospital from January 2018 to February 2020 were equally categorized into two groups according to their treatment method. The control group was administered atorvastatin, and the observation group was administered sodium ozagrel combined with atorvastatin. The National Institutes of Health stroke scale (NIHSS) score, activities of daily living (ADL) score, blood glucose, lipid levels, inflammatory factors, high-mobility group box 1 (HMGB1) levels, paraoxonase-1 (PON-1) levels, erythrocyte sedimentation rate (ESR), and macrophage migration inhibitory factor (MIF) levels were recorded before and after treatment. The total effective rate and adverse reaction rate of the two groups were analyzed. CONCLUSION: Sodium ozagrel with atorvastatin can reduce inflammatory reactions; regulate ESR and HMGB1, PON-1, and MIF levels; control blood glucose and lipid indexes; and alleviate nerve injury without increasing adverse effects of atorvastatin alone.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2021) conducted an observational in Type 2 diabetes and lacunar cerebral infarction (n=82). Sodium ozagrel and atorvastatin vs. Atorvastatin 10-20 mg PO once daily was evaluated on Total effective rate (based on NIHSS score improvement) (p=0.046). Sodium ozagrel combined with atorvastatin significantly increased the total effective rate to 94.0% compared to 80.0% with atorvastatin alone in patients with type 2 diabetes and lacunar cerebral infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: